1
Registered trials
0
Recruiting
1
Unique sponsors
2
Unique IMPs
1
Commercial trials
Drug classes (ATC)
L
Oncology (ATC L)
1
Mechanism of action (INN-stem analysis)
Checkpoint inhibitor (PD-L1)
1 substance
Unknown / small molecule
1 substance
Phase I/II:
1
Phase I/II
1 trial-
EndedOncolytics Biotech Inc. CommercialATEZOLIZUMAB; PELAREOREP
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Oncolytics Biotech Inc. | Commercial | 1 | Phase I/II | 0 |
New trials by year
2024
1